Evidence map›Paper›PMID 34226296›Full record

ArticleAging2021

Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer.

Hung-Chang Wu, Wen-Li Lin, Chien-Liang Lin, Cheng-Yao Lin, Shang-Wen Chen, Yan-Xun Chen, Chao-Hsun Chen, Sung-Wei Lee, Shang-Hung Chen, Chao-Jung Tsao and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Hung-Chang WuDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
Wen-Li LinDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
Chien-Liang LinDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
Cheng-Yao LinDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
Shang-Wen ChenDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
Yan-Xun ChenDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
Chao-Hsun ChenDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
Sung-Wei LeeDepartment of Radiation Oncology, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
Shang-Hung ChenNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Chao-Jung TsaoDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
Wen-Tsung HuangDivision of Hematology and Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
How-Ran GuoDepartment of Environmental and Occupational Health, National Cheng Kung University, Tainan, Taiwan.
Chi Mei Medical Center · TWNational Cheng Kung University · TWNational Cheng Kung University Hospital · TWSouthern Taiwan University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adjuvant concurrent chemoradiotherapy (CCRT) is the standard care for patients with resected advanced gastric cancer, but its survival benefits remain undetermined in patients undergoing D2 lymph node dissection (D2 dissection). We evaluated safety and efficacy of adjuvant CCRT with 5-fluorouracil (5-FU) versus chemotherapy alone in 110 gastric cancer patients with D2 dissection treated in Taiwan between January 2009 and January 2013. All the 71 patients receiving adjuvant CCRT were treated with daily infusional 5-FU and radiotherapy. Adjuvant CCRT was associated with higher risks of major hematologic (56.3% vs. 23.8%,

Indexed as

AgingAdultAgedAged, 80 and overAntimetabolites, AntineoplasticChemoradiotherapy, AdjuvantDisease-Free SurvivalFemaleFluorouracilHumansInfusions, IntravenousLymph Node ExcisionMaleMiddle AgedPrognosisStomach NeoplasmsAntimetabolites, AntineoplasticFluorouracilchemoradiotherapyD2 dissectionelderlygastric cancerinfusional 5-fluorouracil

Identifiers

PMID34226296
PMCPMC8312439
OpenAlexW3179896102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.